title: Streptococcal lung abscesses from a dental focus following tocilizumab: a case report.
abstract: Patients suffering from dental infections and concurrently using immunosuppressive medication are at increased risk of developing systemic streptococcal infections. Tocilizumab is a novel therapeutic agent targeting interleukin-6. We describe a case of streptococcal lung abscesses from a dental focus after use of tocilizumab for treatment of Takayasu arteritis.
authors.affiliation: Department of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, The Netherlands. martijndekruif@gmail.com
authors.forename: Martijn D
authors.initials: MD
authors.lastname: de Kruif
authors.forename: Eric C M
authors.initials: EC
authors.lastname: van Gorp
authors.forename: Elisabeth H
authors.initials: EH
authors.lastname: Bel
authors.forename: Danielle M
authors.initials: DM
authors.lastname: Gerlag
authors.forename: Peter W
authors.initials: PW
authors.lastname: Kunst
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D005260:Female; D005491:Focal Infection, Dental / Q000139:chemically induced* / Q000175:diagnosis / Q000382:microbiology* / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008169:Lung Abscess / Q000139:chemically induced* / Q000175:diagnosis / Q000382:microbiology* / Q000628:therapy; D008875:Middle Aged; D010508:Periodontal Abscess / Q000175:diagnosis / Q000382:microbiology* / Q000628:therapy; D049268:Positron-Emission Tomography; D012390:Root Canal Therapy; D013290:Streptococcal Infections / Q000175:diagnosis / Q000382:microbiology* / Q000628:therapy; D034367:Streptococcus intermedius / Q000302:isolation & purification; D013625:Takayasu Arteritis / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; C502936:tocilizumab